Cardiac Sarcoidosis: The Heart Disease That Hides as Heart Block, Heart Failure, or VT

A 42-year-old man comes to the emergency department with a near-faint while walking up the stairs at work. His EKG shows complete heart block. He has no history of heart disease. He's an active guy, never smoked, normal blood pressure. The cardiology team places a temporary pacemaker, gets an echocardiogram (which shows mildly reduced left ventricular function and a peculiar thinning of the interventricular septum), and then asks the question that changes the trajectory of his care: why does a 42-year-old without coronary disease have complete heart block?

I'm Dr. Damian Rasch, a cardiologist in Encinitas. The answer in many cases like this is cardiac sarcoidosis, and it's one of the more important diagnoses to recognize in modern cardiology because the treatment is meaningfully different from what you'd do for a typical cardiomyopathy. This article walks through what cardiac sarcoidosis is, why it can show up in so many disguises, how we diagnose it, and what the management plan looks like once we know what we're dealing with. The reason I write about this is that cardiac sarcoidosis gets missed often, and when it gets missed, patients can end up with implantable defibrillators they didn't need, transplants they could have avoided, or sudden cardiac death events that were preventable.

What Sarcoidosis Is, Briefly

Sarcoidosis is a multi-system inflammatory disease in which clusters of immune cells, called granulomas, form in various organs. Nobody knows exactly what causes it. The current understanding is that sarcoidosis is a disordered immune response to some unknown trigger (possibly an infectious agent, possibly an environmental antigen) in a person with a genetic predisposition. The lungs are by far the most common site, with hilar lymphadenopathy and lung parenchymal involvement seen in about ninety percent of sarcoidosis patients. The eyes, skin, lymph nodes, liver, and central nervous system can also be affected.

The heart is involved clinically in roughly five to ten percent of patients with systemic sarcoidosis, but autopsy studies have shown cardiac involvement in twenty to thirty percent of all sarcoidosis patients. That means a lot of cardiac sarcoidosis is silent until it isn't. The first symptom can be a heart block, an arrhythmia, heart failure, or sudden death. About a quarter of cardiac sarcoidosis patients present with isolated cardiac disease and no obvious extra-cardiac sarcoidosis at the time of diagnosis, which makes the workup harder.

Cardiac sarcoidosis affects the heart by depositing granulomas in the myocardium. The interventricular septum is a classic location, especially the basal portion. Granulomas in the septum disrupt the conduction system that runs through it, which is why heart block (especially in younger patients) is such a common presentation. Granulomas in the free wall can cause regional wall motion abnormalities, sometimes mimicking ischemic heart disease. Diffuse involvement leads to dilated cardiomyopathy. Late-stage disease can produce aneurysms of the ventricular wall.

The Three Faces of Cardiac Sarcoidosis

When cardiac sarcoidosis presents clinically, it tends to do so in one of three patterns, sometimes overlapping.

1. Conduction Disease (Heart Block)

Atrioventricular block in a younger or middle-aged patient without coronary disease, valvular disease, or a clear medication culprit should raise suspicion for cardiac sarcoidosis. This is one of the more reliable patterns, and it's the one I want every cardiologist and electrophysiologist to recognize. A 35-year-old or 45-year-old who walks in with complete heart block and a structurally near-normal-looking heart on first echo deserves a sarcoidosis workup before getting a permanent pacemaker, because identifying sarcoidosis changes management in important ways. Some patients also present with bundle branch block (especially right bundle branch block) or with new-onset advanced second-degree AV block.

The granulomas that cause conduction disease in cardiac sarcoidosis sit in the basal septum, right in the path of the AV node and the bundle of His. As the granulomas mature and scar, they replace the normal conduction tissue, and the conduction block progresses. Treatment of the underlying inflammation can reverse early block in some cases, although established scar usually doesn't reverse.

2. Ventricular Arrhythmia

Cardiac sarcoidosis is one of the classic causes of ventricular tachycardia in patients with structurally near-normal hearts on initial imaging. The arrhythmia substrate comes from inflammation and scar in the myocardium, often in the basal lateral wall or the basal septum. Sustained VT can be the presenting symptom, sometimes preceded by palpitations or unexplained syncope.

The patients I worry about most are those who present with sudden cardiac arrest. Cardiac sarcoidosis is reported in three to ten percent of younger patients with otherwise unexplained sudden cardiac death. Patients who survive an arrest and turn out to have cardiac sarcoidosis often need both medical therapy for the underlying inflammation and an implantable defibrillator for ongoing arrhythmia protection.

3. Heart Failure

Diffuse cardiac sarcoidosis can produce a dilated cardiomyopathy that looks similar to non-ischemic cardiomyopathy on echo. The clue that something is different is often a focal pattern of late gadolinium enhancement on cardiac MRI, especially in the basal septum or in patchy mid-wall and subepicardial distributions. Patients can present with progressive shortness of breath, leg swelling, exercise intolerance, and the other classic symptoms of heart failure. Without an underlying coronary disease story, sarcoidosis goes high on the differential.

Late-stage cardiac sarcoidosis can produce wall thinning and aneurysm formation, especially in the inferior or lateral walls. These regions can become electrically unstable and produce VT in addition to the contractile dysfunction.

How We Diagnose It

Diagnosing cardiac sarcoidosis is one of the trickier exercises in cardiology because there's no single test that confirms it definitively in most patients. The Heart Rhythm Society's 2014 expert consensus statement laid out criteria that have become the working framework. The criteria distinguish between "histological diagnosis" (granulomas found on cardiac biopsy, which is uncommon) and "clinical diagnosis" (granulomas found in another organ plus appropriate cardiac findings).

A practical workup looks something like this:

First, take a careful history and physical. Cough, dyspnea, eye irritation, skin lesions, lymphadenopathy, and prior diagnoses of "uveitis" or "erythema nodosum" are clues to extra-cardiac sarcoidosis. Family history of sarcoidosis, especially in African American or Scandinavian families (two populations with higher prevalence), is informative.

Second, get an echocardiogram. Look for thinning of the interventricular septum, regional wall motion abnormalities that don't follow a coronary distribution, reduced ejection fraction, and aneurysm formation. Strain imaging can pick up subtle regional dysfunction that the eye misses.

Third, get a cardiac MRI with late gadolinium enhancement. The pattern of LGE in cardiac sarcoidosis is often patchy, mid-wall or subepicardial, and frequently involves the basal septum. The presence of LGE in this distribution in a patient with the right clinical picture is highly suggestive. T2 imaging can identify active edema, which suggests ongoing inflammation rather than burnt-out scar.

Fourth, get an FDG-PET scan with appropriate dietary preparation. The patient eats a high-fat, low-carbohydrate diet for 24 hours and fasts for 12 to 18 hours before the scan. This protocol shifts the heart's metabolism to fatty acid oxidation, which suppresses normal myocardial glucose uptake. Areas of active inflammation continue to take up FDG, lighting up on the PET. PET is uniquely useful for distinguishing active from inactive disease, which has direct treatment implications. PET is also useful for monitoring response to therapy.

Fifth, look for extra-cardiac sarcoidosis. A chest CT or chest X-ray to evaluate for hilar lymphadenopathy and pulmonary involvement, an ophthalmology evaluation for ocular sarcoidosis, a dermatologic evaluation if skin lesions are present, and consideration of biopsy of any accessible site (mediastinal lymph nodes via endobronchial ultrasound, skin lesions, peripheral lymphadenopathy). Finding a granuloma anywhere outside the heart, in a patient with suggestive cardiac findings, satisfies one of the diagnostic criteria.

Sixth, in selected cases where the diagnosis remains uncertain after non-invasive workup, consider endomyocardial biopsy. The yield is low because the granulomas are patchy, but image-guided biopsy targeted to areas of PET uptake or MRI enhancement has improved the diagnostic yield in expert centers.

Why Getting It Right Matters

The reason I push for a structured workup is that cardiac sarcoidosis behaves differently from other cardiomyopathies in ways that change management.

First, cardiac sarcoidosis responds to immunosuppression. Corticosteroids and steroid-sparing agents like methotrexate or azathioprine can reduce inflammation, prevent progression of scar, and in some cases reverse early conduction disease or cardiomyopathy. None of that benefit accrues to a patient who's been mislabeled as non-ischemic cardiomyopathy and put only on standard heart failure medications.

Second, the threshold for ICD implantation is different. Patients with cardiac sarcoidosis and any of several risk markers (LV dysfunction, LGE on MRI, history of syncope, history of VT, abnormal electrophysiology study) are at higher arrhythmic risk than ejection fraction alone would suggest. The 2014 HRS consensus statement recommends ICD placement at lower thresholds than would be used for typical non-ischemic cardiomyopathy.

Third, the response to standard heart failure therapy is different. Beta-blockers, ACE inhibitors or ARBs or sacubitril/valsartan, MRAs, and SGLT2 inhibitors are still important, but they treat the consequences of the inflammation rather than the inflammation itself. Adding immunosuppression to the standard four-pillar regimen is what gives patients the best chance of reversing or stabilizing the underlying disease.

Fourth, transplant outcomes are affected. Patients who receive a heart transplant for end-stage cardiac sarcoidosis without ongoing immunosuppression for sarcoidosis can have recurrent disease in the transplanted heart. Knowing the diagnosis matters even at the transplant stage.

Treatment

Treatment of cardiac sarcoidosis has three layers: anti-inflammatory therapy targeted at the granulomas, anti-arrhythmic therapy targeted at the electrical complications, and standard heart failure therapy targeted at the contractile complications.

Immunosuppression

Corticosteroids are the first-line treatment for active cardiac sarcoidosis, defined by uptake on FDG-PET, edema on cardiac MRI, or active inflammatory cells on biopsy. Prednisone is typically started at 30 to 40 mg daily, with a slow taper over six to twelve months. Higher doses are sometimes used in patients with severe presentations, but the side effect profile of prolonged high-dose steroids is substantial, so most patients are tapered down over time.

Steroid-sparing agents are added in patients who can't tolerate prolonged steroids, who have refractory disease, or who relapse during steroid taper. Methotrexate is the most commonly used agent, with azathioprine and mycophenolate as alternatives. In refractory cases, infliximab and other anti-TNF biologics have been used, although the evidence base for these in cardiac sarcoidosis is smaller. The decision to add a steroid-sparing agent is usually made in coordination with rheumatology or pulmonary specialists who manage sarcoidosis regularly.

Treatment response is followed clinically (symptoms, EKG, echo), with serial cardiac MRI when relevant, and with FDG-PET to track resolution of active inflammation. PET is the most useful test for confirming that the inflammation is quiet, which informs decisions about steroid taper.

Antiarrhythmic and Device Therapy

Bradyarrhythmias from conduction system involvement often require permanent pacing. The HRS guidelines have moved toward implanting devices with both pacing and defibrillation capability (a CRT-D or ICD with pacing) in cardiac sarcoidosis patients who need pacing, since arrhythmic risk is elevated even after the conduction disease is treated.

Sustained VT or aborted sudden death is an indication for implantable defibrillator placement. Catheter ablation is sometimes used for VT that is medication-refractory, although the substrate in cardiac sarcoidosis can be difficult to ablate completely because of the patchy and progressive nature of the disease.

Antiarrhythmic medications, especially amiodarone or sotalol, are sometimes added in patients with frequent VT episodes despite ICD therapy. Beta-blockers help with both rate control and arrhythmia suppression and are part of the standard regimen.

Heart Failure Therapy

Patients with cardiac sarcoidosis and reduced ejection fraction benefit from the four-pillar HFrEF regimen: beta-blockers, ACE inhibitors or ARBs or sacubitril/valsartan, MRAs like spironolactone or eplerenone, and SGLT2 inhibitors like dapagliflozin or empagliflozin. The same long-term outcome benefits seen in other HFrEF populations apply here, with the added consideration that the underlying disease can progress or relapse, requiring closer monitoring and willingness to escalate.

Patients who progress to advanced heart failure despite optimized therapy may be candidates for left ventricular assist devices or heart transplantation. The advanced heart failure team needs to know about the sarcoidosis diagnosis because of the implications for ongoing immunosuppression and risk of recurrence.

Prognosis

The prognosis of cardiac sarcoidosis varies widely depending on how it presents and how early it's caught. Patients with isolated conduction disease, normal LV function, and minimal LGE on MRI tend to do well with appropriate medical management. Patients with reduced ejection fraction, extensive scar, or sustained VT have a worse trajectory and require closer surveillance and more aggressive treatment.

Five-year survival in published series ranges from 60 to 90 percent depending on the cohort, with the highest mortality in patients with advanced ventricular dysfunction or refractory arrhythmias. The single biggest determinant of long-term outcome is probably how early the diagnosis is made and how reliably treatment is started. Patients who get a clear diagnosis early in the course of their disease and who get on appropriate immunosuppression often have stabilization or improvement of their cardiac function. Patients whose diagnosis is delayed or missed for years tend to present with more advanced disease.

When to Suspect It

Cardiac sarcoidosis should be on the differential in several specific scenarios.

A younger or middle-aged patient with new-onset second-degree or third-degree AV block, especially in the absence of clear coronary disease, valvular disease, or medication effects. The under-50 patient with complete heart block is the canonical example.

A patient with sustained ventricular tachycardia and a structurally near-normal-appearing heart on initial echo, especially when the VT comes from a basal location.

A patient with new-onset non-ischemic cardiomyopathy without a clear etiology after standard workup, especially when there are areas of regional wall motion abnormality that don't follow a coronary distribution, or when the basal septum looks thinned.

A patient with a known sarcoidosis diagnosis (pulmonary, ocular, dermatologic) who develops cardiac symptoms, palpitations, syncope, or new EKG abnormalities. These patients deserve cardiac MRI and PET as part of their workup, even if the cardiac findings are subtle.

A patient with a family history of sarcoidosis who develops unexplained cardiac symptoms. The familial component is real, even if the inheritance pattern is complex.

When to Escalate Care

Call 911 immediately for severe lightheadedness or syncope, sustained palpitations, severe shortness of breath, or chest pain. Patients with known cardiac sarcoidosis are at elevated risk of sudden arrhythmic events, and any of these symptoms deserves immediate evaluation.

Contact your cardiologist the same day for new palpitations, presyncope, worsening exercise tolerance, or new fluid retention. Cardiac sarcoidosis can progress despite stable-appearing baseline status, and same-day evaluation catches relapses early.

Schedule a clinic visit within one to two weeks for non-specific symptoms or for any concerns about steroid side effects, since prolonged steroid therapy carries its own risk profile (weight gain, glucose intolerance, osteoporosis, infection risk) that needs ongoing management.

Common Patient Questions

Could I have cardiac sarcoidosis without lung sarcoidosis?

Yes. About a quarter of patients with cardiac sarcoidosis have isolated cardiac disease at presentation, with no clinically apparent involvement of the lungs, eyes, skin, or lymph nodes. This is part of why the diagnosis is harder than it sounds. The workup includes looking carefully for extra-cardiac involvement (chest CT, ophthalmology evaluation, dermatology evaluation, sometimes whole-body PET), but in some patients the only organ affected is the heart. Endomyocardial biopsy is sometimes used in these isolated cases when the diagnosis is uncertain after non-invasive workup, although yield is low.

Why am I being asked to do a special diet before my PET scan?

FDG-PET imaging of the heart requires that the heart's normal sugar uptake be suppressed so that any abnormal sugar uptake (which marks active inflammation) becomes visible. The way we do this is by shifting the heart's metabolism to fat instead of glucose for 24 hours before the scan. That means a high-fat, low-carbohydrate, no-sugar diet for 24 hours followed by a 12 to 18 hour fast. If the diet isn't followed correctly, the PET scan can be uninterpretable, with the entire heart muscle taking up tracer and obscuring any signal from inflammation. This is the single most important pre-scan instruction. If you're confused about what to eat, ask the imaging center for written instructions.

Will I need to be on prednisone forever?

Probably not, but treatment courses are usually long. A typical initial course of prednisone runs six to twelve months at progressively lower doses. After the inflammation is quiet on PET imaging and clinical symptoms have stabilized, the steroid is tapered slowly. Some patients can be successfully tapered off completely. Others need a low maintenance dose (often 5 to 10 mg of prednisone daily) plus a steroid-sparing agent like methotrexate or azathioprine to keep the inflammation suppressed. The plan is individualized based on disease activity, treatment response, and side effect tolerance.

If my pacemaker is for sarcoidosis, do I need a defibrillator too?

Often yes. Patients who need pacing for cardiac sarcoidosis-related conduction disease are also at higher arrhythmic risk than the conduction disease alone would suggest. The granulomas that disrupted the conduction system are usually accompanied by other granulomas in the myocardium that can produce dangerous arrhythmias. Current HRS guidelines recommend implanting a device with defibrillation capability (an ICD or CRT-D rather than a plain pacemaker) in most cardiac sarcoidosis patients who need pacing. The exact recommendation depends on additional factors like ejection fraction, MRI findings, electrophysiology study results, and individual risk factors.

Can cardiac sarcoidosis go into remission?

Yes, in many cases. Active inflammation can be suppressed with treatment, and the heart can remain stable for years or even decades. Some patients have a single inflammatory episode that responds to a year of immunosuppression and then never relapses. Others have a relapsing-remitting course requiring intermittent treatment escalation. A smaller number have progressive disease despite optimal therapy. Imaging surveillance with periodic cardiac MRI and PET helps identify relapses early.

Is it hereditary?

There's a familial component to sarcoidosis in general, with first-degree relatives at modestly increased risk. The genetics are complex and don't follow a simple Mendelian pattern. Cardiac sarcoidosis on its own does not have established screening recommendations for asymptomatic relatives. If a relative develops symptoms suggestive of sarcoidosis, the workup is the same as it would be for anyone with those symptoms, with the family history factored into the pretest probability.

Can I exercise?

In most cases, yes, with some considerations. Patients with stable cardiac sarcoidosis, normal or near-normal ejection fraction, and no significant arrhythmia history can usually engage in moderate aerobic exercise. Patients with active inflammation, recent VT, or significant LV dysfunction need a more conservative approach. Cardiac rehabilitation is a useful structured environment for return to exercise after the diagnosis. The threshold for restricting activity is set by the cardiologist based on individual disease characteristics, not by a generic rule.

A Final Note From Me

Cardiac sarcoidosis is one of those diagnoses that rewards pattern recognition. Once you've seen a few cases, the pattern becomes recognizable: a younger patient with conduction disease that doesn't fit a coronary story, a non-ischemic cardiomyopathy with a thinned basal septum, a VT substrate in someone whose heart looks too normal on echo. These patterns should trigger the workup, because the alternative is missed disease that progresses silently.

If you've been given a cardiac sarcoidosis diagnosis, the most important things are getting on appropriate immunosuppression, getting the right device when needed, and staying engaged with surveillance imaging and clinical follow-up. Patients who do those three things well often do remarkably well. The disease can be stabilized for years. Treatments have improved meaningfully over the last decade. And the prognosis for an early-diagnosed, well-treated cardiac sarcoidosis patient is dramatically better than the prognosis for a patient whose diagnosis was missed for years and who presents in advanced heart failure or with sudden cardiac arrest.

If you have a younger family member or friend with new-onset heart block or unexplained ventricular arrhythmia, the question of cardiac sarcoidosis deserves to be raised. Most cardiologists are familiar with the diagnosis, but the workup is involved enough that it's worth asking explicitly. The patients I worry about are the ones whose pacemaker went in without a sarcoidosis evaluation. The patients I'm hopeful about are the ones who got the right diagnosis and the right treatment plan early in the course of their disease.

References

1. Birnie, David H., William H. Sauer, Frank Bogun, et al. "HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated with Cardiac Sarcoidosis." Heart Rhythm 11, no. 7 (2014): 1305-1323.

2. Crouser, Elliott D., Lisa A. Maier, Kevin C. Wilson, et al. "Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline." American Journal of Respiratory and Critical Care Medicine 201, no. 8 (2020): e26-e51.

3. Chen, Eugene S., and David R. Moller. "Cardiac Sarcoidosis." Clinics in Chest Medicine 36, no. 4 (2015): 657-668.

4. Yazaki, Yoshikazu, Morie Sekiguchi, Toshio Naito, et al. "Comparison of Clinical Features and Prognosis of Cardiac Sarcoidosis and Idiopathic Dilated Cardiomyopathy." American Journal of Cardiology 88, no. 9 (2001): 1006-1010.

5. Kandolin, Riina, Jukka Lehtonen, Jukka Airaksinen, et al. "Cardiac Sarcoidosis: Epidemiology, Characteristics, and Outcome over 25 Years in a Nationwide Study." Circulation 131, no. 7 (2015): 624-632.

6. Sadek, Mouhannad M., Tracy Yung, Andrew C. T. Ha, et al. "Corticosteroid Therapy for Cardiac Sarcoidosis: A Systematic Review." Canadian Journal of Cardiology 29, no. 9 (2013): 1034-1041.

7. Blankstein, Ron, Marcio Sommer Bittencourt, Ross M. Kirschner, et al. "Cardiac Positron Emission Tomography Enhances Prognostic Assessments of Patients with Suspected Cardiac Sarcoidosis." Journal of the American College of Cardiology 63, no. 4 (2014): 329-336.

8. Hulten, Edward, Stephanie Aslam, Michael Osborne, Siddique Abbasi, Marcio Sommer Bittencourt, and Ron Blankstein. "Cardiac Sarcoidosis: State of the Art Review." Cardiovascular Diagnosis and Therapy 6, no. 1 (2016): 50-63.

9. Greulich, Simon, Christof Sebastian Deluigi, Stefanie Gloekler, et al. "CMR Imaging Predicts Death and Other Adverse Events in Suspected Cardiac Sarcoidosis." JACC: Cardiovascular Imaging 6, no. 4 (2013): 501-511.

10. Ribeiro Neto, Manuel L., Gosta B. Pettersson, Carmela D. Tan, Nathaniel L. Smedira, and Daniel A. Culver. "Heart Transplantation in Patients with Cardiac Sarcoidosis." Journal of Heart and Lung Transplantation 41, no. 6 (2022): 727-734.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.